2015-2016 Master of Music Recital - August Berger (Double Bass)

Curso de especialidad en la carrera de Ingeniería Industrial de carácter teórico-práctico dirigido a los estudiantes del quinto ciclo que busca desarrollar las competencias generales de Pensamiento Crítico y Pensamiento innovador y la competencia específica ABET:k.1) Usa técnicas destrezas y herramientas modernas necesarias en la practica de la ingeniería.El curso desarrolla las metodologías y técnicas para representar y mejorar procesos así como para para establecer los tiempos estándar de los mismos. El objetivo final es aumentar la productividad de la empresa

PENINGKATAN HASIL BELAJAR SISWA PADA MATERI CIRI-CIRI KHUSUS YANG DIMILIKI HEWAN MELALUI MODEL KOOPERATIF TIPE TALKING STICK DI KELAS VI MIN MESJID RAYA BANDA ACEH

Pelaksanaan pembelajaran Sains yang baik tergantung antara lain pada cara guru menyajikan materi, mengelola kelas dan menggunakan model pembelajaran yang aktif, kreatif dan menyenangkan. Salah satu model pembelajaran yang dapat membangkitkan motivasi belajara siswa adalah model pembelajaran Kooperatif Tipe Talking Stick yang merupakan salah satu cara yang efektif untuk membuat suasana belajar siswa untuk berdiskusi dan kerjasama di kelas sehingga siswa termotivasi untuk belajar dan memperoleh hasil belajar sesuai dengan yang diharapkan. Penelitian ini bertujuan (1) Untuk mengetahui kemampuan guru dalam mengajarkan sains pada materi ciri-ciri khusus yang dimiliki kewan dengan menggunakan model kooperatif tipe Talking Stick. (2) Untuk mengetahui aktivitas siswa pada saat belajar Sains pada materi ciri-ciri khusus yang dimiliki hewan melalui model kooperatif tipe Talking Stick. (3) Mengetahui hasil belajar siswa setelah belajar Sains pada materi ciri-ciri khusus yang dimiliki hewan melalui model kooperatif tipe Talking Stick. Penelitian ini menggunakan jenis Penelitian Tindakan Kelas (PTK atau Classroom Action Research). Penelitian ini dilakukan melalui dua Siklus. Tehnik pengumpulan data dilakukan dengan menggunakan Lembar observasi kemampuan guru dan aktivitas siswa serta Soal Test. Kemudian data ini dianalisis dengan menggunakan rumus persentase. Hasil penelitian yang diperoleh adalah, (a) Kemampuan guru meningkat dari 83% pada siklus I menjadi 93% pada siklus II. (b) Aktivitas siswa meningkat dari 88% pada siklus I menjadi 94% pada siklus II. (c) Hasil tes prestasi belajar siklus I 58% meningkat menjadi 92% pada siklus II. Berdasarkan hasil penelitian dapat disimpulkan bahwa dengan menggunakan model pembelajaran Kooperatif Tipe Talking Stick pada pembelajaran Sains siswa lebih aktif, dan hasil belajarnya meningkat

PENERAPAN PEMBELAJARAN JELAJAH ALAM SEKITAR (JAS) TERHADAP AKTIVITAS BELAJAR SISWA PADA MATERI KEANEKARAGAMAN HAYATI DI KELAS X SMAN 1 PEUSANGAN

Penelitian tentang “Penerapan Pembelajaran Jelajah Alam Sekitar (JAS) terhadap Aktivitas belajar siswa pada materi Keanekaragaman Hayati di kelas X SMAN 1 Peusanganâ€, telah dilaksanakan pada tanggal 10-22 April 2013. Bertujuan untuk mengetahui aktivitas belajar siswa siswa kelas X SMAN 1 Peusangan setelah diterapkan pembelajaran Jelajah Alam Sekitar pada materi Keanekaragaman Hayati. Metode yang digunakan dalam penelitian ini yaitu metode eksperimen. Populasi dalam penelitian ini adalah seluruh siswa kelas X SMAN 1 Peusangan, sedangkan yang dijadikan sampel yaitu siswa kelas X4 sebagai kontrol dan X6 sebagai kelas eksperimen. Pengambilan sampel pada penelitian ini dilakukan secara random sampling. Pengumpulan data dari data aktivitas belajar siswa dengan menggunakan teknik non test. Analisis data aktivitas belajar dilakukan dengan rumus persentase. Hasil analisis data dari nilai rata-rata aktivitas visual kelas eksperimen adalah 86,67%, aktivitas lisan adalah 81,67%, aktivitas mendengarkan adalah 92%, aktivitas menulis adalah 83,33%, aktivitas mental adalah 80%, dan aktivitas emosional adalah 80%. Dan nilai rata-rata aktivitas visual kelas kontrol adalah 50%, aktivitas lisan adalah 66,67%, aktivitas mendengarkan adalah 62,5%, aktivitas menulis adalah 76,67%, aktivitas mental adalah 65% dan aktivitas emosional adalah 60%

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Ingeniería De Métodos-IN147-201202

El curso desarrolla los principios de la mejora de métodos de trabajo y la medición de trabajo conjuntamentecon los principios ergonómicos para adaptar el trabajo sistemas productos y ambiente a las capacidades físicasy mentales del trabajador. El fin primordial de estas decisiones no se dirige solo a aumentar la productividad dela empresa sino a buscar también el bienestar del trabajador

Ingeniería De Métodos-IN147-201200

El curso desarrolla los principios de la mejora de métodos de trabajo y la medición de éste conjuntamente con los principios ergonómicos para adaptar el trabajo sistemas productos y ambiente a las capacidades físicas y mentales del trabajador logrando como el fin primordial no solo aumentar la productividad de la empresa sino que también el bienestar del trabajador

Ingeniería De Métodos-IN147-201200

El curso desarrolla los principios de la mejora de métodos de trabajo y la medición de éste conjuntamente con los principios ergonómicos para adaptar el trabajo sistemas productos y ambiente a las capacidades físicas y mentales del trabajador logrando como el fin primordial no solo aumentar la productividad de la empresa sino que también el bienestar del trabajador

Ingeniería De Métodos-IN147-201202

El curso desarrolla los principios de la mejora de métodos de trabajo y la medición de trabajo conjuntamentecon los principios ergonómicos para adaptar el trabajo sistemas productos y ambiente a las capacidades físicasy mentales del trabajador. El fin primordial de estas decisiones no se dirige solo a aumentar la productividad dela empresa sino a buscar también el bienestar del trabajador